<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01238107</url>
  </required_header>
  <id_info>
    <org_study_id>MT-102-2001</org_study_id>
    <nct_id>NCT01238107</nct_id>
  </id_info>
  <brief_title>A Clinical Study With MT-102 in Subjects With Cancer Cachexia</brief_title>
  <official_title>A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase II Clinical Study to Evaluate Doses of MT-102 in Subjects With Cachexia Related to Stage III and IV Non-small Cell Lung Cancer and Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PsiOxus Therapeutics Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Veeda Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PsiOxus Therapeutics Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II clinical study to evaluate MT-102 administered over a sixteen week period in&#xD;
      subjects with cachexia related to non-small cell lung cancer and colorectal cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cachexia is a wasting disease, associated with significant morbidity and mortality,&#xD;
      accompanying a wide range of serious illnesses, for which there are currently no widely&#xD;
      approved therapeutic agents. Cachexia is defined as weight loss, associated with a chronic&#xD;
      underlying disease, of at least 5% in 12 months or less. It is associated with fatigue, loss&#xD;
      of muscle strength, a low fat free index and neurohormonal and biochemical abnormalities.&#xD;
&#xD;
      Cancer cachexia occurs in about a third of all patients with cancer and has been estimated to&#xD;
      be the direct cause of death in up to 20% of all cancer related deaths. As with other solid&#xD;
      tumours, colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) have relatively high&#xD;
      incidences of cachexia, approximately 28% and 34% respectively.Through its combined&#xD;
      pharmacological actions, MT-102 has a multi-functional effect upon three potential&#xD;
      pharmacological targets, each of which is relevant for cancer cachexia&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstrate the effect of a 10mg / bd dose of MT-102 in comparison to placebo on the rate of weight change over a sixteen week period in patients with cachexia related to underlying stage III and stage IV colorectal or non-small cell lung cancer</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Cancer Cachexia</condition>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-102</intervention_name>
    <description>BETA BLOCKER</description>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Adult patients aged between 25 to 80 years of age and with a life expectancy of&#xD;
             greater than 3 months as judged by the treating physician.&#xD;
&#xD;
             2. Confirmed diagnosis of one of:&#xD;
&#xD;
             a. Non-curative stage III or stage IV Colorectal Cancer (CRC) not suitable for&#xD;
             surgery, or b. Non-curative stage III or stage IV Non-small Cell Lung Cancer (NSCLC)&#xD;
             not suitable for surgery;&#xD;
&#xD;
             3. Patients who are receiving or who have already received a course of chemotherapy,&#xD;
             with or without radiotherapy or surgery, with one of the following regimes:&#xD;
&#xD;
             a. For non-small cell lung cancer, a platinum based regimen b. For colorectal cancer,&#xD;
             a 5FU or Irinotecan based regimen&#xD;
&#xD;
             4. Cachexia with ongoing weight loss that in the opinion of the investigator is due to&#xD;
             the underlying cancer.&#xD;
&#xD;
             5. Evidence of cachexia as judged by one of:&#xD;
&#xD;
             a. ≥5% documented weight loss in the previous 12 months; or b. A subjective report of&#xD;
             weight loss in the previous 12 months and a recorded body mass index (BMI) less than&#xD;
             20.0 kg/m2 c. Ongoing documented weight loss of at least 1kg in the week prior to day&#xD;
             0; or 1.25kg in the 2 weeks prior to day 0, or 1.5kg in the 3 to 6 weeks prior to day&#xD;
             0; provided that BMI is not more than 25.&#xD;
&#xD;
             6. At least two of the following:&#xD;
&#xD;
             a. Subjective report of decreased muscle strength b. Subjective report of fatigue c.&#xD;
             Subjective report of anorexia d. Abnormal biochemistry with one or more of the&#xD;
             following: i. CRP &gt; ULN (as per Central Lab normal value) ii. Anemia (&lt; 12 g/dl) iii.&#xD;
             Low serum albumin (&lt; 3.2 g/dl) 7. Patients of childbearing potential must use an&#xD;
             effective method of avoiding pregnancy (including oral, transdermal, or implanted&#xD;
             contraceptives; an intrauterine device; male or female condoms; diaphragm or cervical&#xD;
             cap with spermicide; or abstinence) prior to randomisation and must agree to continue&#xD;
             using such precautions until the end of the 140 day safety follow up; 8. Willing and&#xD;
             able to comply with the protocol and to complete the study period; 9. Willing to&#xD;
             forego other forms of experimental treatment during the study; 10. Signed and dated&#xD;
             informed consent, prior to receipt of any study medication or any study related&#xD;
             procedures.&#xD;
&#xD;
             11. ECOG performance status 0, 1 or 2 12. Able to complete the performance tests (SCP,&#xD;
             SMWT, SPPB, HGS) at the screening visit and with two consecutive pre-randomisation&#xD;
             SMWT results that differ by no more than 30% from each other 13. At least 80%&#xD;
             compliant during the placebo run in period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. 1. Pregnancy or lactation at screen or baseline visit;&#xD;
&#xD;
          2. ≥20% weight loss in the previous 3 months or a BMI of less than 16 kg/m2&#xD;
&#xD;
          3. Age greater than 80 or less than 25 at baseline visit;&#xD;
&#xD;
          4. Scheduled to start any new course of chemotherapy or to undergo a change in present&#xD;
             chemotherapeutic regimen during the dose escalation phase of the study (the first&#xD;
             three weeks after randomisation);&#xD;
&#xD;
          5. Any surgical procedure within the past month or any planned surgical procedure;&#xD;
&#xD;
          6. Any mechanical obstruction of the alimentary canal;&#xD;
&#xD;
          7. Any history or evidence of intractable vomiting;&#xD;
&#xD;
          8. A history or clinical evidence of any hyperthyroidism, cirrhosis, hepatic failure,&#xD;
             HIV, renal failure (as determined by a serum creatinine &gt; 250µmol/l or &gt; 2.83 mg/dl at&#xD;
             screen) or active tuberculosis (as confirmed by sputum or other microbiological&#xD;
             methods, within the last five years);&#xD;
&#xD;
          9. Any physical, medical, socioeconomic or other non-cancer related cause for simple&#xD;
             starvation, muscle wasting or weight loss;&#xD;
&#xD;
         10. Receiving enteral tube feeding or parenteral nutrition at screening or baseline visit;&#xD;
&#xD;
         11. Any clinical evidence of ascites or significant oedema or significant pleural effusion&#xD;
             at screening or baseline visit;&#xD;
&#xD;
         12. Current or planned treatment with&#xD;
&#xD;
               1. Any oral adrenal corticosteroids (inhaled or topical steroids and short-term use&#xD;
                  of dexamethasone around the time of chemotherapy are acceptable);&#xD;
&#xD;
               2. Beta adrenergic blockers,&#xD;
&#xD;
               3. Non-dihydropyridine calcium antagonists (e.g. Verapamil, diltiazem),&#xD;
&#xD;
               4. Alpha adrenergic blockers,&#xD;
&#xD;
               5. Ivabradine (Coralan, Procoralan),&#xD;
&#xD;
               6. 5HT agonists or antagonists e.g. SSRI's, , (short-term use around the time of&#xD;
                  chemotherapy are acceptable)&#xD;
&#xD;
               7. MAOI's,&#xD;
&#xD;
               8. Beta agonists, (short term or on-and -off use of inhaled broncho-dilators are&#xD;
                  acceptable)&#xD;
&#xD;
               9. Amiodarone,&#xD;
&#xD;
              10. Megestrol, Anabolic Steroids or any other prescription medication intended to&#xD;
                  increase appetite or to treat unintentional weight loss.&#xD;
&#xD;
         13. Treatment with any investigational drug therapy within 28 days prior to the screening&#xD;
             visit;&#xD;
&#xD;
         14. Previous history of administration of pindolol or s-pindolol;&#xD;
&#xD;
         15. History of allergy or reaction to any component of the MT 102/study drug formulation;&#xD;
&#xD;
         16. History or presence of congestive heart failure (with LVEF &lt;45%) or uncontrolled&#xD;
             hypertension (with BP &gt;160/95 mm Hg);&#xD;
&#xD;
         17. Use of a pacemaker, implantable defibrillator, or internalized metal stent;&#xD;
&#xD;
         18. Resting pulse rate less than 68 beats per minute or high degree conduction defect on&#xD;
             the electrocardiogram;&#xD;
&#xD;
         19. A resting supine systolic blood pressure less than 100 mm Hg.&#xD;
&#xD;
         20. A history of bronchospasm and bronchial asthma;&#xD;
&#xD;
         21. History or diagnosis of brain metastases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kumar n Pradhash, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>TATA MEMORIAL HOSPITAL , MUMBAI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite Hospital Virchow-Klinikum Campus</name>
      <address>
        <city>Berlin</city>
        <zip>d-13352</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumaran Hospital Private Ltd</name>
      <address>
        <city>Kilpauk</city>
        <state>Chennai</state>
        <zip>10</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Kamakshi Memorial Hospital</name>
      <address>
        <city>Pallikaranai</city>
        <state>Chennai</state>
        <zip>600100</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vedanta Institute of Medical Science</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shree Krishna Hopsital</name>
      <address>
        <city>Anand</city>
        <state>Gujarat</state>
        <zip>388325</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kailash Cancer Hospital &amp; Research Centre</name>
      <address>
        <city>Goraj</city>
        <state>Gujarat</state>
        <zip>391760</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TATA Memorial Hopsital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Curie Manavta Cancer Centre</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <zip>422004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shatabdi Super Speciality Hospital</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <zip>422005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Noble Hopsital</name>
      <address>
        <city>Pune</city>
        <zip>411013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sultahan Bahiyah</name>
      <address>
        <city>Alor Setar</city>
        <state>Kedha</state>
        <zip>05460</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universiti Sains Malaysia</name>
      <address>
        <city>Kubang Kerian</city>
        <state>Kelantan</state>
        <zip>16150</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universiti Kebangsaan Malaysia</name>
      <address>
        <city>Cheras</city>
        <state>Kuala Lumpur</state>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universiti Malaya Medical</name>
      <address>
        <city>Jalan Baharu</city>
        <state>Kuala Lumpur</state>
        <zip>50603</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tuanku Ja'afar Hospital</name>
      <address>
        <city>Seremban</city>
        <state>Negeri Sembilan</state>
        <zip>70300</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Islamic University Malaysia</name>
      <address>
        <city>Kuantan</city>
        <state>Pahang</state>
        <zip>25200</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penang General Hopsital</name>
      <address>
        <city>Pulau Pinang</city>
        <state>Penang</state>
        <zip>10990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Umum Sarawak</name>
      <address>
        <city>Kuching</city>
        <state>Sarawak</state>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>India</country>
    <country>Malaysia</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>November 9, 2010</study_first_submitted>
  <study_first_submitted_qc>November 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2010</study_first_posted>
  <last_update_submitted>September 9, 2014</last_update_submitted>
  <last_update_submitted_qc>September 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cachexia</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wasting Syndrome</mesh_term>
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

